[Selective occlusion of ocular neovascularization by photodynamic therapy]

U Schmidt1, R Birngruber, T Hasan

  • 1Wellman Laboratories of Photomedicine, Harvard Medical School, Boston.

Insights

Photodynamic therapy (PDT) offers a novel approach to selectively target and occlude neovascularizations in the eye. By utilizing specific dye properties and carrier-mediated delivery, this method spares healthy vessels, enhancing treatment precision.

Area of Science:

  • Ophthalmology
  • Biomedical Engineering
  • Photochemistry

Context:

  • Photodynamic therapy (PDT) is established for vascular occlusion.
  • Neovascularization presents a therapeutic challenge in intraocular diseases.
  • Selective targeting of pathological vasculature is crucial for effective treatment.

Purpose:

  • To enhance the selectivity of PDT for intraocular neovascularizations.
  • To investigate strategies for sparing physiological vessels during PDT.
  • To develop carrier-mediated PDT for improved efficacy and safety.

Summary:

  • PDT induces vascular occlusion through endothelial damage and thrombosis.
  • Two strategies enhance selectivity: prolonged dye retention (phthalocyanine) and carrier-mediated delivery (chlorin e6-LDL).
  • Phthalocyanine selectively thromboses neovascularizations while sparing normal vessels; ce6-LDL targets proliferating cells via LDL receptors, achieving photothrombosis at low doses.

Impact:

  • Carrier-mediated PDT offers a sensitive and selective approach for treating intraocular neovascularizations.
  • This method holds potential for improved outcomes in conditions like wet age-related macular degeneration.
  • Sparing physiological vasculature minimizes side effects and improves patient safety.